- Home
- VNCE vs BLRX Comparison
VNCE vs BLRX Comparison
Compare VNCE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNCE
- BLRX
- Stock Information
- Founded
- VNCE 2002
- BLRX 2003
- Country
- VNCE United States
- BLRX Israel
- Employees
- VNCE N/A
- BLRX N/A
- Industry
- VNCE Clothing/Shoe/Accessory Stores
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- VNCE Consumer Discretionary
- BLRX Health Care
- Exchange
- VNCE Nasdaq
- BLRX Nasdaq
- Market Cap
- VNCE 20.2M
- BLRX 17.0M
- IPO Year
- VNCE 2013
- BLRX 2011
- Fundamental
- Price
- VNCE $1.57
- BLRX $3.72
- Analyst Decision
- VNCE Strong Buy
- BLRX Strong Buy
- Analyst Count
- VNCE 3
- BLRX 2
- Target Price
- VNCE $4.17
- BLRX $19.00
- AVG Volume (30 Days)
- VNCE 28.5K
- BLRX 35.4K
- Earning Date
- VNCE 09-15-2025
- BLRX 08-14-2025
- Dividend Yield
- VNCE N/A
- BLRX N/A
- EPS Growth
- VNCE N/A
- BLRX N/A
- EPS
- VNCE N/A
- BLRX N/A
- Revenue
- VNCE $292,214,000.00
- BLRX $22,340,000.00
- Revenue This Year
- VNCE $1.93
- BLRX N/A
- Revenue Next Year
- VNCE $4.91
- BLRX N/A
- P/E Ratio
- VNCE N/A
- BLRX N/A
- Revenue Growth
- VNCE 1.46
- BLRX 91.68
- 52 Week Low
- VNCE $1.02
- BLRX $2.30
- 52 Week High
- VNCE $6.89
- BLRX $35.02
- Technical
- Relative Strength Index (RSI)
- VNCE 53.89
- BLRX 36.88
- Support Level
- VNCE $1.45
- BLRX $3.35
- Resistance Level
- VNCE $1.62
- BLRX $4.17
- Average True Range (ATR)
- VNCE 0.09
- BLRX 0.29
- MACD
- VNCE 0.00
- BLRX -0.06
- Stochastic Oscillator
- VNCE 76.19
- BLRX 26.43
About VNCE Vince Holding Corp.
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.